Pfizer Follows Novartis; Offers To Up Stake In Indian Arm To 75 Percent
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - After Novartis and Mylan, it's now Pfizer's turn to increase its equity holding in its Indian operations. In an announcement to the Bombay Stock Exchange, Pfizer said it has decided to acquire an additional stake of 33.77 percent in Pfizer India through an open offer from public shareholders at a price of 675 rupees per share ($13.23)
You may also be interested in...
GSK Pumps In $1 Billion To Raise Equity In Indian Pharma Subsidiary
GSK said it will infuse $1 billion to purchase shares and raise its stake in its Indian arm to 75%, the highest limit allowed in India. Brushing aside the growth setback in the last few months, the British firm reaffirmed a long view of the Indian health care market.
Listing Of MNC Divisions In India Has Been Rough Ride With Stray Sparks Of Hope
Large pharmaceutical companies realize the importance of emerging markets, including India, and are now calling for easing of restrictions and a level playing field.
Listing Of MNC Divisions In India Has Been Rough Ride With Stray Sparks Of Hope
Large pharmaceutical companies realize the importance of emerging markets, including India, and are now calling for easing of restrictions and a level playing field.